DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for epididymitis — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpididymitis maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epididymitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
GATA binding protein 3 (GATA3) — GATA3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4HC9 · 1.6 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2002 survey of 50 men with chronic epididymitis (average symptom duration 4.9 years, average age 46) found that only 16% were reasonably satisfied with their quality of life. The average pain score was 4.7 out of 10. Although 66% thought about their symptoms some or a lot, only 30% said symptoms kept them from usual activities. The most common previous treatments recalled were antibiotics (74%) and anti-inflammatory agents (36%); at the time of the survey 26% were on some type of pain medication. No significant epidemiological, sexual, medical or associated factors distinguished these patients from 20 controls. The authors proposed a classification system (inflammatory, obstructive, epididymalgia) and a symptom assessment index.
A 1985 review of 123 cases of acute epididymitis classified patients by severity at admission into three groups: those manageable as outpatients, those requiring admission, and those at high risk for complications. The authors stated this system provided an objective method for monitoring progress. A 2022 expert review notes that most acute epididymitis is caused by bacterial infection, typically sexually transmitted organisms or urinary pathogens, but that current treatment regimens remain empirical. The review states that relatively sparse direct trial data exists on antimicrobial treatments for acute epididymitis, and that much guidance is derived from previous recommendations and knowledge of antimicrobial activities rather than from dedicated trials.
A 2014 case report describes a patient who developed epididymitis after 17 months of low-dose amiodarone therapy (100 mg per day). The authors note that amiodarone aggregates and triggers inflammation in the head of the epididymis. In this case, the drug was not stopped or dose-reduced, yet the epididymitis resolved with analgesics alone, which the authors describe as a distinct case in the urological literature. They stress that amiodarone should be considered in the differential diagnosis of epididymitis.
What is still missing are prospective, controlled trials of antibiotic regimens for acute epididymitis, as current guidance relies on extrapolation from other infections. For chronic epididymitis, no effective treatment has been established in a trial; the condition remains poorly understood, with no clear aetiology and no validated management strategy beyond symptom control. Funding for such trials, better patient stratification, and standardised outcome measures are all lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Urology · 2002 · 69 citations
The Patient With Chronic Epididymitis: Characterization Of An Enigmatic Syndrome
AbstractPURPOSE: We provide a baseline description of men diagnosed with chronic epididymitis, explore relevant associations that may be important etiological factors and suggest a classification system and specific symptom assessment tool. MATERIALS AND METHODS: Men diagnosed with chronic epididymitis, described as symptoms of discomfort or pain at least 3 months in duration in the scrotum, testicle or epididymis localized to 1 or each epididymis on clinical examination, completed an extensive specific clinical inventory questionnaire. Evaluation included demographics, preceding and concurrent clinical history, duration since diagnosis, associated and previous clinical associations, frequency and severity of prostatitis, voiding and sexual symptoms, specific and general quality of life, and history of investigation and/or treatment for the condition. Volunteers with no past or concurrent history of chronic epididymitis completed similar clinical inventory questionnaires. RESULTS: A total of 50 consecutive men 21 to 83 years old (average age 46) diagnosed with chronic epididymitis who had an average symptom duration of 4.9 years (range 0.25 to 29) were enrolled in the study. The average pain score plus or minus standard deviation was 4.7 +/- 2.1 (range 0 to 10). Of the men 16% were reasonably satisfied with their quality of life. Although 66% of the patients thought about the symptoms some or a lot, in only 30% did symptoms keep them from doing the kinds of things that they would usually do. The most common previous therapies recollected by the patients were antibiotics (74%) and anti-inflammatory agents (36%). At the time of the survey 26% of the men were on some type of pain medication. There were no significant epidemiological, sexual, medical or associated factors that differentiated patients with chronic epididymitis from the 20 controls. A chronic epididymitis classification system (inflammatory, obstructive and epididymalgia) and a symptom assessment index based on assessing pain and quality of life-impact was developed. CONCLUSIONS: This comprehensive clinical survey of men diagnosed with chronic epididymitis is the first step for defining and characterizing this particular population. Development of a classification system and symptom assessment index may direct further studies in the etiology, epidemiology and management of chronic epididymitis.
AbstractOne-hundred and twenty-three cases of acute epididymitis are reviewed. The patients were placed into one of three categories according to severity of involvement at the time of admission and their clinical course retrospectively reviewed. This classification system identified patients who could be successfully managed as outpatients, patients who required admission, and patients at high risk for the development of complications. This system also provided an objective method of monitoring patient progress.
Iranian Red Crescent Medical Journal · 2014 · 10 citations · open access
Amiodarone Induced Epididymitis: A Case Report
AbstractINTRODUCTION: Amiodarone is an effective drug for life-threatening arrhythmias like recurrent ventricular fibrillation and atrial fibrillation. Amiodarone creates rarely genitourinary side effects are seen. These are epididymitis, testicular dysfunction and impotance. Amiodarone aggregates and triggers inflammation in the head of the epididym. CASE REPORT: We present the case of a patient who developed epididymitis after 17 months of amiodarone therapy, using a low dose (100 mg per day). Although cessation of medication or dose lowering was not performed, remission of the patient only by analgesics is a distinct case reported in urological literature. CONCLUSIONS: This case stresses the importance of considering an adverse effect of amiodarone treatment as a cause when making a differential diagnosis of epididymitis.
Expert Opinion on Pharmacotherapy · 2022 · 5 citations
Advances in the antibiotic management of epididymitis
AbstractINTRODUCTION: Acute epididymitis is commonly encountered and typically presents acutely within a wide clinical spectrum. Most cases of acute epididymitis are caused by bacterial infection, most often by sexually transmitted organisms and urinary pathogens. Current treatment regimens remain empirical, although recent advances using modern diagnostic techniques support a change in the management paradigm. AREAS COVERED: The choice of the initial antibiotic regimen is empirical and based on the most likely causative pathogen, whether sexually transmitted, enteric, or other. Adherence of clinical practice remains short of available guidance, which may be improved by thorough clinical and microbiologic assessment, supported by a knowledge of the commonly associated pathogenic organisms, and the appropriate choice of tests required for their identification. The use of advanced microbiology techniques and studies of current practice provide new insights that have challenged traditional management paradigms. The authors discuss these points and provide their expert perspectives on its treatment and future developments. EXPERT OPINION: Relatively sparse direct trial data exists on antimicrobial treatments for acute epididymitis. Much of the presently available guidance is derived from previous guidance recommendations, knowledge of antimicrobial activities of specific agents, and treatment outcomes in uncomplicated infections. Identification of specific pathogens and prescribing accuracy is dependent on the extent to which cases are investigated and is therefore variable.
Bulletin of Siberian Medicine · 2012 · 0 citations · open access
Comparative analysis of methods for the treatment of acute epididymitis in children
AbstractThe results of treatment of acute epididymitis is analyzed. The materials were 101 patients aged 17 years, catamnesis followed in terms of 1 to 10 years. We used a conservative, surgical and puncture treatment method proposed by the authors. Analyzed clinical, ultrasound and Doppler sonography parameters. It is shown that best results are obtained with conservative treatment, the results of treatment are comparable to puncture them for efficiency, with surgical intervention results are less satisfactory.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
